Regenxbio (RGNX) Operating Leases (2019 - 2025)

Regenxbio's Operating Leases history runs 7 years deep, the most recent figure standing at $65.2 million for Q4 2025.

• In Q4 2025, Operating Leases fell 12.03% year-over-year to $65.2 million; the TTM figure through Dec 2025 stood at $65.2 million (down 12.03% YoY), while the FY2025 annual figure was $65.2 million, down 12.03% from the prior year.
• Operating Leases was $65.2 million for Q4 2025 at Regenxbio, down from $67.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $88.8 million in Q4 2022 to a low of $65.2 million in Q4 2025.
• Historically, Operating Leases has averaged $79.6 million across 5 years, with a median of $82.3 million in 2021.
• The sharpest annual moves came in 2021 and 2025: Operating Leases jumped 1062.78% in 2021, then slipped 12.03% in 2025.
• A 5-year view of Operating Leases shows it stood at $84.9 million in 2021, then grew by 4.56% to $88.8 million in 2022, then fell by 7.41% to $82.2 million in 2023, then slipped by 9.84% to $74.1 million in 2024, then decreased by 12.03% to $65.2 million in 2025.
• The last three Operating Leases figures came in at $65.2 million (Q4 2025), $67.4 million (Q3 2025), and $69.6 million (Q2 2025), per Business Quant data.